The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending acoramidis for marketing authorization in the European Union (EU).…
Takeda is hosting an investor R&D Day today, starting at 8:30 a.m. JST in Tokyo. The event will highlight the company’s late-stage pipeline, focusing on its transformative potential for patients…
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for the treatment of adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS). This decision is based…
Eli Lilly and Company announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending Omvoh® (mirikizumab) for approval. Omvoh,…
AbbVie has announced a definitive agreement to acquire Nimble Therapeutics, a biotech company specializing in the discovery and development of innovative oral peptide therapies. This acquisition includes Nimble’s lead investigational…
Merck known as MSD outside the United States and Canada, announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending…
Updated results from the OlympiA Phase III trial revealed that AstraZeneca and MSD’s Lynparza (olaparib) continues to show significant, clinically meaningful improvements in overall survival (OS), invasive disease-free survival (IDFS),…
Pfizer and Alliance Foundation Trials, LLC (AFT) recently unveiled findings from the Phase 3 PATINA trial, highlighting the potential of IBRANCE (palbociclib) in improving outcomes for patients with hormone receptor-positive…
Cyrus Biotechnology, Inc. has announced new data demonstrating the potent activity of its engineered IgG-degrading enzyme, CYR241, in a rabbit redosing model. Importantly, the study revealed that CYR241 does not…
SonarMD, a leading platform for value-based care (VBC) focused on complex, chronic gastrointestinal conditions, has presented new clinical findings at the Advances in Inflammatory Bowel Diseases (AIBD) conference in Orlando,…
The global market for Antisense & RNAi therapeutics is poised for significant growth, with projections estimating its value at US$5.4 billion in 2024. This market is expected to expand at…
Menarini Group, Stemline Therapeutics, and MEDSIR have presented groundbreaking research on the ADELA clinical trial, which targets therapeutic resistance in advanced ER+/HER2- breast cancer. This research was shared at the…